牛牛AI助理已提取核心訊息
Cybin Inc., a clinical-stage biopharmaceutical company, announced on February 7, 2024, that it has been granted two additional patents in Japan, enhancing its intellectual property portfolio for its DMT program. The patents, expected to last until at least 2040 and 2041, cover synthesis methods and injectable formulations for DMT and deuterated DMT, which are in development for treating Generalized Anxiety Disorder (GAD). CEO Doug Drysdale highlighted the strategic importance of these patents in one of the world's largest pharmaceutical markets. The company also reported progress on its investigational new drug, CYB004, with the U.S. FDA clearing its application, allowing Phase 2a studies to commence in Q1 2024. Cybin's research pipeline includes other investigational psychedelic-based compounds for mental health disorders, with CYB003 and CYB004 being developed for major depressive disorder and GAD, respectively. Cybin operates internationally with a focus on revolutionizing mental healthcare through psychedelic-based therapeutics.
Cybin Inc., a clinical-stage biopharmaceutical company, announced on February 7, 2024, that it has been granted two additional patents in Japan, enhancing its intellectual property portfolio for its DMT program. The patents, expected to last until at least 2040 and 2041, cover synthesis methods and injectable formulations for DMT and deuterated DMT, which are in development for treating Generalized Anxiety Disorder (GAD). CEO Doug Drysdale highlighted the strategic importance of these patents in one of the world's largest pharmaceutical markets. The company also reported progress on its investigational new drug, CYB004, with the U.S. FDA clearing its application, allowing Phase 2a studies to commence in Q1 2024. Cybin's research pipeline includes other investigational psychedelic-based compounds for mental health disorders, with CYB003 and CYB004 being developed for major depressive disorder and GAD, respectively. Cybin operates internationally with a focus on revolutionizing mental healthcare through psychedelic-based therapeutics.
處於臨床階段的生物製藥公司Cybin Inc. 於2024年2月7日宣佈，它已在日本獲得另外兩項專利，從而增強了其DMT計劃的知識產權組合。這些專利預計將至少持續到2040年和2041年，涵蓋DMT和Deuterated DMT的合成方法和注射製劑，這些製劑正在開發中，用於治療廣泛性焦慮症（GAD）。首席執行官道格·德賴斯代爾強調了這些專利在全球最大的製藥市場之一中的戰略重要性。該公司還報告了其研究性新藥 CYB004 的進展，美國食品藥品管理局批准了其申請，允許在2024年第一季度開始2a期研究。Cybin的研究渠道包括其他用於治療精神健康障礙的研究性迷幻藥化合物，CYB003 和 CYB004 分別正在開發用於重度抑鬱症和GAD。Cybin在國際上開展業務，專注於通過基於迷幻藥的療法徹底改變心理保健。
處於臨床階段的生物製藥公司Cybin Inc. 於2024年2月7日宣佈，它已在日本獲得另外兩項專利，從而增強了其DMT計劃的知識產權組合。這些專利預計將至少持續到2040年和2041年，涵蓋DMT和Deuterated DMT的合成方法和注射製劑，這些製劑正在開發中，用於治療廣泛性焦慮症（GAD）。首席執行官道格·德賴斯代爾強調了這些專利在全球最大的製藥市場之一中的戰略重要性。該公司還報告了其研究性新藥 CYB004 的進展，美國食品藥品管理局批准了其申請，允許在2024年第一季度開始2a期研究。Cybin的研究渠道包括其他用於治療精神健康障礙的研究性迷幻藥化合物，CYB003 和 CYB004 分別正在開發用於重度抑鬱症和GAD。Cybin在國際上開展業務，專注於通過基於迷幻藥的療法徹底改變心理保健。
有用
沒用